https://www.optimumcomms.com/wp-content/uploads/2024/10/Ottimo_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-12-19 08:24:592024-12-19 08:24:59Ottimo Pharma Raises over $140 Million in Series A Financing
https://www.optimumcomms.com/wp-content/uploads/2024/10/Ottimo_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-12-19 08:24:592024-12-19 08:24:59Ottimo Pharma Raises over $140 Million in Series A Financing
Novo Holdings and SUBRA join forces to accelerate development of innovative superconductor technology for power transmission and fusion energy
Today, Novo Holdings and SUBRA announce a partnership to fast-track…

Novo Nordisk Foundation grants €134.1 million to establish the Biotechnology Research Institute for the Green Transition (BRIGHT) in Denmark
A new comprehensive initiative at the Technical University of…

Denmark’s new AI supercomputer Gefion ranked as 7th fastest storage systems in the world
Denmark's state-of-the-art AI supercomputer, Gefion, has achieved…

NeoPhore appoints Michael Shih as Chief Executive Officer
Highly experienced corporate development leader with a track…

Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion
Licensing agreement gives Elevation Oncology access to Synaffix's…

Neuraxpharm and Pharmathen enter into strategic co-development agreement to develop long-acting injectable therapies
New therapies will allow patients greater choice and flexibility…

General Inception acquires Enable Medicine and announces strategic partnership to accelerate drug discovery with AI-led generative biological search
Enable Medicine is at the forefront of using generative AI…

SpliceBio Announces U.S. FDA IND Clearance of SB-007 to Commence Phase 1/2 Clinical Study in Patients with Stargardt Disease
SB-007 is the only IND-cleared, clinical-stage therapeutic…

Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy
Statistically significant difference in arrested disease in leriglitazone…

iOnctura reaches new clinical milestones in uveal melanoma
Completed Phase I DIONE-01 study demonstrates clinical activity…

Ariceum Therapeutics and NorthStar Medical Radioisotopes Announce Supply Agreement for Therapeutic Radioisotope Actinium-225
NorthStar will supply non-carrier added Actinium-225, a radionuclide,…

Noema Pharma extends Series B financing round, closing at CHF130 Million ($147 Million)
EQT Life Sciences expands the Series B with additional capital,…

Resolution Therapeutics Announces Presentation at Keystone Symposia on Fibrosis
Edinburgh and London, UK, 10 December 2024 – Resolution Therapeutics…

Poolbeg Pharma plc presents POLB 001 pre-clinical study data at the 66th American Society of Hematology (ASH) Annual Meeting
All doses of POLB 001 significantly reduced clinically observed…

NICE Recommends ublituximab (BRIUMVI®▼) as an Option for Treating Relapsing-Remitting Multiple Sclerosis (RRMS)
London, UK, Barcelona, Spain and Düsseldorf, Germany – 5…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York